News › Industry News, News

ITC Favors Allergan Partner Medytox Over Daewoong in Botulinum Toxin Strain Dispute

July 10, 2020

The U.S. International Trade Commission (ITC) has sided with South Korean drugmaker Medytox Inc. in a dispute, saying its local rival Daewoong Pharmaceutical Co. stole trade secrets on a botulinum toxin strain, industry officials here said Tuesday.
In its preliminary verdict, the ITC also advised that imports of Daewoong Pharmaceutical’s botulinum toxin products be banned in the United States over the next 10 years.Read more at the Yonhap News Agency >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • SkinStylus Receives New FDA Clearance for the Improvement of Periorbital Wrinkles for All Skin Types
    • GlossGenius Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • FDA Advisory Committee to Review Seven Peptides for Potential Use in Compounding
    • Medicare GLP-1 Bridge Program Launches July 1, Expanding Access for Some Patients
    • Universal Healthcare Consulting Becomes Platinum Vendor Affiliate with the American Med Spa Association
Advertisement